Quantcast
Last updated on April 18, 2014 at 8:18 EDT

Latest Anti-glycoprotein-210 antibodies Stories

2014-04-14 10:59:02

Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC. Obeticholic acid at both a 10 mg dose and a 5 mg dose titrated to...

2012-02-02 22:34:48

Drug found to be safe in PBC patients not responsive to ursodeoxycholic acid An open-label study of rituximab, a monoclonal antibody for human CD20, was shown to be safe in patients with primary biliary cirrhosis (PBC) who had an incomplete response to the standard ursodeoxycholic acid (UDCA) therapy, also known as Ursodiol. Study details available in the February issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver...

2011-03-31 22:49:19

International study shows substantial efficacy of Obeticholic Acid as a treatment option Results from an international study presented today at the International Liver Congress have shown Obeticholic Acid (OCA) is a safe and effective treatment in patients suffering from Primary Biliary Cirrhosis (PBC) as demonstrated by substantial decreases in the levels of alkaline phosphatase (AP) enzyme in the blood, a key marker for PBC. In this double blind parallel group study, 59 patients received 10...

2011-03-31 12:00:00

NEW YORK, March 31, 2011 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., today announced positive results from a 59 patient, placebo controlled, double-blind Phase II clinical trial of obeticholic acid (OCA) given as monotherapy to patients with primary biliary cirrhosis (PBC). The study evaluated the effects of 10 mg and 50 mg of OCA compared with placebo in patients with elevated alkaline phosphatase (AP). AP is a liver enzyme routinely used to evaluate the clinical status and disease...

2010-04-13 07:00:00

NEW YORK, April 13 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., today announced the presentation of the results from its recently completed Phase II clinical trial of INT-747 (obeticholic acid) in patients with primary biliary cirrhosis (PBC). The oral presentation will take place during the Opening Session of the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) on April 15, 2010. About the INT-747 Phase II Clinical Trial in Patients with PBC...

2010-03-24 09:17:05

Case-control studies of risk factors for primary biliary cirrhosis in 2 United Kingdom populations Hair dye and smoking both increase the risk of progressive liver disease, suggests research involving around 5000 people published in the journal Gut. Primary biliary cirrhosis (PBC), which is an early form of liver cirrhosis, is a long term progressive autoimmune disease, in which environmental factors are thought to play a part. It causes the liver's plumbing system of bile ducts to become...